Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Standard of care guidelines improve outcomes in coronary heart disease patients

26 Jun 2020

Achieving standard of care (SOC) targets, such as reduced levels of low-density lipoprotein cholesterol (LDL-C) and glycated haemoglobin (HbA1c), improves outcomes in coronary heart disease (CHD) patients, a new study has found.

The study included 13,623 patients (mean age, 64.3±9.2 years; 18.4 percent female) in whom SOC targets were defined as blood pressure (BP) <140/90 mm Hg and LDL-C <100 mg/dL and <70 mg/dL. Additionally, in those with diabetes, HbA1c <7 percent and BP <130/80 mm Hg were included as recommendations. The development of major adverse cardiovascular events (MACEs) was set as an outcome.

After a median follow-up of 3.7 years, MACEs were reported in 10.4 percent of patients on placebo, and in 9.7 percent of those who were treated with darapladib.

After the first year, 42.6 percent of the participants satisfied the more lenient LDL-C goal of <100 mg/dL. This led to a significantly lower risk of developing MACEs (hazard ratio [HR], 0.694, 95 percent confidence interval [CI], 0.594–0.811; p<0.001).

During the same time span, 31.8 percent of patients were able to meet the more stringent LDL-C threshold of <70 mg/dL, which also correlated with a significant drop in the risk of MACEs, albeit to a weaker extent (HR, 0.834, 95 percent CI, 0.708–0.983; p=0.031).

Moreover, 44.0 percent of those with diabetes were able to achieve the HbA1c guideline of <7 percent concentration. This likewise exerted a strong and significant protective effect against MACEs (HR, 0.653, 95 percent CI, 0.522–0.815; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.